Charles River Laboratories Intl. Inc vs e l f Beauty Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $299.21 (market cap $14.23B), while e l f Beauty Inc trades at $108.42 (market cap $6.25B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.3× e l f Beauty Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and e l f Beauty Inc for 25 Days on average.
| CRL | ELF | |
|---|---|---|
Market Cap | $14.23B | $6.25B |
Volume | 1,176,885 | 1,099,552 |
Sector | Health | Consumer Staples |
52-Week High | $310.77 | $144.97 |
52-Week Low | $149.93 | $49.57 |
Typical Hold Time | 33 Days | 25 Days |
Enterprise Value | $17.06B | $6.84B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company shows robust revenue growth, expanding internationally with the rhode brand launch in Europe via Sephora, though net margins are thin at 3.38%. Valuation ratios are elevated with a P/E of 108.12, reflecting high growth expectations. Analyst consensus is mixed with a 48.27% buy rating but a price target of $95.91 below the current price.
Outlook: ELF's aggressive marketing and global expansion present growth opportunities, but the stock's premium valuation and high P/E pose risks if growth slows. Investor sentiment is cautiously optimistic, supported by institutional buying, yet overbought RSI levels suggest near-term volatility. Key risks include execution of international strategy and competitive pressures in the beauty sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →